This article will provide an overview of the evolving nature of cancer treatment, the benefits and challenges of these new treatments, and the leadership strategies required to manage the evolution from a system perspective. The number and complexity of novel cancer therapies, while offering improved patient outcomes, has become a challenge for the healthcare system due to the high cost of these new therapies. In Canada, the implementation of the pan-Canadian Oncology Drug Review and the pan-Canadian Pharmaceutical Alliance helps to streamline the review and negotiating process and to ensure consistency across provinces. Strategies to support these processes include ensuring safe patient treatment, patient counselling, clinician education, and practice innovation.
Introduction
Cancer is the name given to a group of related diseases which are characterized by abnormal cell growth. Usually, human cells grow and divide to form new cells on a constant cycle to repair and replace old cells. However, when cancer develops, this process is disrupted and cells grow in an uncontrolled fashion. This may result in solid tumours and may result in spread throughout the body. There are over 100 types of cancer and these are usually named based on the organ or tissue of origin, such as breast cancer or follicular lymphoma.
The management of cancer is complex and evolving. The most common treatment strategies include surgery, radiation therapy, and systemic therapy. Systemic therapy is rapidly advancing. Chemotherapy, the use of drugs to kill cancer cells, has been augmented by the addition of hormone therapy, stem cell transplant, and newer treatment options including immunotherapy, targeted therapy, and personalized (or precision) medicine. 1 Cancer treatment often involves the combination of two or more cancer treatments together in one protocol. This may include the combination of surgery, radiation, and systemic therapy, and it may involve the use of two or more medications at the same time. Cancer treatments may be given by injection, for example, by intravenous or subcutaneous routes of administration, or it may be given orally. The number of oral treatments has increased significantly in recent years. Oral treatments can be taken at home and can be a helpful option for patients. However, this does come with an increased need for patient education on managing side effects and ensuring adherence.
Immunotherapy uses medications to stimulate the body's natural immune system to fight cancer. Non-specific immunotherapies such as interferon were the first medications in this class. The immune checkpoint pathways, programmed cell death-1, programmed death ligand-1, and cytotoxic T-lymphocyteassociated protein-4 have been identified as important to the immune system's ability to control cancer growth. Blocking these pathways with immune checkpoint inhibitors such as ipilimumab, nivolumab, and pembrolizumab allows the body's immune system to stop or slow cancer growth. There continues to be research and two other forms of immunotherapy are oncolytic virus therapy, in which genetically modified viruses are used to stimulate an immune response, and T-cell therapy, in which a patient's T cells are modified to have receptors designed to recognize cancer cells.
Targeted therapy uses medications to target specific genes and proteins unique to cancer cells that have a critical role in tumour growth or progression. Examples of targeted therapy include rituximab for the treatment of lymphoma and trastuzumab for the treatment of metastatic breast cancer.
In personalized medicine, tests are done on a patient's specific tumour to determine potential treatment options based on their predicted response to that treatment. This helps determine which medication to select. Personalized medicine is not always a routine part of care for patients yet, but specific types and stages of cancer are more likely to be tested. For example, two such tests are OncoPanel and the Myeloid Panel.
With the advent of these new treatment options, which provide the potential for improved patient outcomes and quality of life, there are also challenges to the healthcare system. Challenges include ensuring patient safety, managing toxicity, adherence to treatment, treatment duration, and cost. Health leaders are charged with ensuring access to care while managing the impacts of these new treatments. In this article, we will discuss the benefits and challenges that leadership and the health system are facing.
Discussion
New treatment options in cancer care can offer benefits to the individual patient. The potential benefit is, of course, improved patient outcomes as defined by overall survival, improved progression-free survival, improved response rates, reduced symptoms, and improved quality of life. Overall survival is defined as the length of time from either the date of diagnosis or the start of treatment that the patient is alive. It is considered the gold standard for determining efficacy of a treatment, but other outcomes are also important. Progression-free survival is the length of time from the start of treatment that the patient lives with the disease but it does not get worse. Measuring other benefits, such as quality of life and symptom control, is more difficult, but validated tools such as the European Organization for Research and Treatment of Cancer QLQ-C30 quality of life instrument help to quantify the benefit to patients. 2 When a disease is considered life-threatening, the importance of positive patient outcomes becomes even more significant and there is a societal expectation that these advances in care should be made available to patients as quickly as possible. For patients, these new medications can make a large difference in the length and quality of life.
However, these new therapies come at a cost. [3] [4] [5] Oncology drugs and high cost seem to be synonymous. 3, 4 In the United States, it is estimated that the annual cost of a new cancer treatment exceeds $100,000 and drug prices have increased by 13% each year from 2000 to 2015. 3, 6, 7 In Canada, total drug expenditure was $33 billion in 2012, with an annual growth rate of approximately 4% per year. 8 In an already strained healthcare system, the cost of oncology medications combined with the large number of promising molecules in the pipeline is intimidating. Interestingly enough, the price is not always correlated with efficacy. 7 BC Cancer provides a comprehensive cancer control program for the province of British Columbia. Since the 1980s, the BC Cancer tumour groups have developed treatment protocols to help define the treatment population and guide clinicians in the delivery of the treatment and the management of side effects. The tumour groups constantly update the available treatment options for patients and can both recommend the addition of new treatments and the delisting of older or less effective protocols. The BC Cancer funded 15 new treatment protocols in 2016, and during the same time, 2 were delisted. The number of active protocols has grown to over 400 for the treatment of adult cancers. Stem cell transplantation and pediatric protocols add to the total.
Around the world, jurisdictions are wrestling with the issues and working to develop methodology to assist in the decisionmaking process. [8] [9] [10] [11] [12] [13] [14] [15] The American Society of Clinical Oncology, the European Society of Medical Oncology, and the Canadian Agency for Drugs and Technologies in Health (CADTH) Pan-Canadian Oncology Drug Review (pCODR) are examples of these frameworks. Factors considered in the frameworks vary but include clinical benefit, patient values, costeffectiveness, and economic and organizational feasibility. 6 Clinical benefit includes effectiveness, safety, burden of illness, and need. 6 Safety and toxicity of the treatment regimen must be considered. The newer agents have a different toxicity profile than traditional chemotherapy and staff education is needed to ensure that the patient is well managed during treatment. Cost-effectiveness is a measure of the net cost or efficiency of the new treatment compared to current treatment options. However, this is sometimes difficult to quantify due to uncertainties with the available data, such as the potential length of therapy. These frameworks continue to evolve to meet the needs of patients, clinicians, and funding authorities. 14 In Canada, the process for decision-making involves a number of steps. It starts with Health Canada approval for the medication. Health Canada will approve a medication when it is determined to be safe and effective. 13 The Patented Medicine Prices Review Board sets a maximum limit on the price that the manufacturer can charge to ensure that drug prices remain reasonable. 13 The CADTH pCODR (for oncology medications) and the CADTH Common Drug Review (CDR; for nononcology medications) complete an evidence-based assessment of the medication or treatment regimen and make a recommendation to the provinces and territories to help guide funding decisions. 13 Once a positive recommendation is received from CADTH pCODR or CDR, the Pan-Canadian Pharmaceutical Alliance (pCPA) will negotiate with the manufacturer to set the price of the medication across Canada. The pCPA was established in August 2010 and conducts joint provincial/territorial negotiations for brand name drugs to achieve the best possible value for publicly funded drug programs and patients across the country. 8 This includes both cancer and non-cancer drugs. Although on a global scale, Canada is a relatively small market, it is still significant, and this makes it possible for the pCPA to negotiate prices on a pan-Canadian basis. As of April 1, 2016, including both oncology and non-oncology medications, pCPA has successfully completed 95 joint negotiations on brand name drugs and price reductions on 18 generic drugs, resulting in an estimated $712 million in combined savings annually. 15 Once a national price has been agreed upon, provinces can proceed to listing. This helps to ensure consistent pricing across the country and facilitates the ability of all provinces to fund a particular treatment. Ensuring alignment across the country ensures access to medications for patients at an equitable price. This allows smaller provinces to receive the same price as larger provinces so that patients living in a smaller province do not have to pay more for the same treatment as a patient living in a larger province. The challenge remains, though, for provinces to determine how they can afford to fund these new and expensive treatments.
Although cancer treatment is considered a specialized area, cancer is a common disease seen across the spectrum of patients, both ambulatory and in the inpatient setting. With the aging population and with population growth in general, cancer incidence will continue to grow. 16 In addition, as we add new treatments, we also increase the number of times that patient could potentially access care. Where in the past, a patient might have only received one line of therapy, it is now common for patients to receive multiple lines of therapy and for longer durations.
Funding considerations are not in isolation, and cancer funding is only one small part of the total healthcare budget. Because cancer budgets are typically coordinated within each province or territory, a nationally coordinated approach makes logical sense. However, it may be possible for other parts of the healthcare system to consider some of the strategies being used in the cancer field. As leaders within the healthcare system, whether within the oncology field or not, we can support the national strategies for the review and pricing negotiation processes. In the future, there may be some difficult decisions around the priority for implementation, based on the ability of the system to afford the budget impact. Implementation and ensuring compliance with approved treatment protocols help to ensure that the system can stay on target from a budget perspective. This also will ensure the safest possible practice. There must be educational efforts for both clinicians and patients. Patients are a key element of the success of the treatment. Adherence for oral treatments is an important factor in efficacy, so ensuring that the patient and family understand the drug and the dosing regimen are required. Innovation in practice is also an important element to ensure that the healthcare system can continue to cope with the number of patients and to ensure that the treatment facilities remain as efficient as possible. This includes the potential for creative scheduling to streamline healthcare provider contact and minimize drug wastage, optimizing physician computer order entry or the use of preprinted orders and evolution in care models.
Conclusion
Cancer treatment continues to evolve and develop. This provides significant hope for patients but is not without challenges in the healthcare system. The development of CADTH pCODR and pCPA has helped to streamline the health technology assessment and ensure consistency in funding across the provinces and territories. The system will continue to be challenged as the number of cancer patients grows and the number of new treatment options increases.
